71 related articles for article (PubMed ID: 12396608)
21. Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques.
Mason RD; De Rose R; Kent SJ
Virology; 2009 Jun; 388(2):315-23. PubMed ID: 19394064
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?
O'Connor D; Allen T; Watkins DI
Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques.
Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP
J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322
[TBL] [Abstract][Full Text] [Related]
24. An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection.
Smith SM; Pentlicky S; Klase Z; Singh M; Neuveut C; Lu CY; Reitz MS; Yarchoan R; Marx PA; Jeang KT
J Biol Chem; 2003 Nov; 278(45):44816-25. PubMed ID: 12947089
[TBL] [Abstract][Full Text] [Related]
25. Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge.
Mortara L; Letourneur F; Villefroy P; Beyer C; Gras-Masse H; Guillet JG; Bourgault-Villada I
Virology; 2000 Dec; 278(2):551-61. PubMed ID: 11118377
[TBL] [Abstract][Full Text] [Related]
26. Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes.
Peyerl FW; Barouch DH; Letvin NL
Viral Immunol; 2004; 17(2):144-51. PubMed ID: 15279695
[TBL] [Abstract][Full Text] [Related]
27. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
[TBL] [Abstract][Full Text] [Related]
28. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals.
Belliard G; Romieu A; Zagury JF; Dali H; Chaloin O; Le Grand R; Loret E; Briand JP; Roques B; Desgranges C; Muller S
Vaccine; 2003 Jul; 21(23):3186-99. PubMed ID: 12804847
[TBL] [Abstract][Full Text] [Related]
29. Lymphoproliferative responses in macaques immunized with inactivated SIV vaccine.
Teng XC; Ashworth LA; Sharpe SA; Dennis MJ; Cranage MP
AIDS Res Hum Retroviruses; 1993 Aug; 9(8):799-801. PubMed ID: 8217348
[No Abstract] [Full Text] [Related]
30. Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursors.
Kakimoto WM; Gettie A; Smith S; Donahoe SM; Jin X; Marx P; Connor R; Nixon DF
Immunol Lett; 1999 Mar; 66(1-3):135-40. PubMed ID: 10203046
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with Rev and Tat against AIDS.
Osterhaus AD; van Baalen CA; Gruters RA; Schutten M; Siebelink CH; Hulskotte EG; Tijhaar EJ; Randall RE; van Amerongen G; Fleuchaus A; Erfle V; Sutter G
Vaccine; 1999 Jun; 17(20-21):2713-4. PubMed ID: 10418922
[No Abstract] [Full Text] [Related]
32. CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo.
Petravic J; Loh L; Kent SJ; Davenport MP
J Virol; 2008 Apr; 82(8):4091-101. PubMed ID: 18272587
[TBL] [Abstract][Full Text] [Related]
33. Macaque models for AIDS vaccine development.
Johnson RP
Curr Opin Immunol; 1996 Aug; 8(4):554-60. PubMed ID: 8794019
[TBL] [Abstract][Full Text] [Related]
34. Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.
Zolla-Pazner S
AIDS; 2016 Oct; 30(16):2551-2553. PubMed ID: 27753680
[No Abstract] [Full Text] [Related]
35. Use of simian immunodeficiency virus for evaluation of AIDS vaccine strategies.
Daniel MD; Desrosiers RC
AIDS; 1989; 3 Suppl 1():S131-3. PubMed ID: 2558686
[No Abstract] [Full Text] [Related]
36. Progress in vaccine development against SIV and HIV.
Bolognesi DP
J Acquir Immune Defic Syndr (1988); 1990; 3(4):390-4. PubMed ID: 1690288
[No Abstract] [Full Text] [Related]
37. AIDS research. New findings cast doubt on UK vaccine trials.
Anderson C
Nature; 1991 Sep; 353(6342):287. PubMed ID: 1822967
[No Abstract] [Full Text] [Related]
38. Anti-HIV vaccines. Current status and future developments.
Norley SG; Vogel T; Kurth R
Drugs; 1993 Dec; 46(6):947-60. PubMed ID: 7510612
[No Abstract] [Full Text] [Related]
39. The mechanistic analysis of founder virus data in challenge models.
Ortega-Villa AM; Nason MC; Follmann D
Stat Med; 2021 Sep; 40(20):4492-4504. PubMed ID: 34111904
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic T lymphocytes and vaccine development 2011.
Xiao Z; Klonowski K; Yang H; Curtsinger J
J Biomed Biotechnol; 2011; 2011():756864. PubMed ID: 22619488
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
